10-Q: Fortrea Holdings Inc. Reports Q3 2024 Results: Revenue Declines Amidst Strategic Shift

Fortrea Holdings Inc. reported a decrease in revenue for the third quarter of 2024, alongside a net loss, as the company continues to navigate its strategic transition following its spin-off and the sale of its Enabling Services segment.

Summary

• Fortrea Holdings Inc. reported a revenue of $674.9 million for the third quarter of 2024, a 5.4% decrease compared to $713.8 million in the same period of 2023.
• The company experienced a net loss of $27.9 million for the quarter, compared to a net loss of $14.0 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, revenue was $1,999.4 million, a 6.3% decrease from $2,132.8 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $267.3 million, compared to a net income of $29.3 million for the same period in 2023.
• The company's backlog was $7.6 billion as of September 30, 2024.
• The decrease in revenue was primarily driven by lower service revenues and decreased pass-through costs.
• Selling, general, and administrative expenses increased by 27.6% in the third quarter and 28.4% in the first nine months of 2024, due to costs associated with becoming a standalone company and exiting the Transition Services Agreement with Labcorp.
• The company sold its Enabling Services Segment in the second quarter of 2024 for $340 million, resulting in a loss on disposal of $23.2 million.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to declining revenue, net losses, and increased expenses. While the company has a significant backlog and has completed a strategic sale, the overall financial performance is concerning, and the identified material weaknesses in internal controls add to the negative sentiment.

Positives

• The company completed the sale of its Enabling Services Segment, which is expected to allow for greater focus on its core Clinical Services segment.
• The company has a significant backlog of $7.6 billion, indicating future revenue potential.
• The company has implemented a three-year $300 million accounts receivable securitization program to improve cash flow.

Negatives

• The company experienced a decrease in revenue for both the third quarter and the first nine months of 2024.
• The company reported a net loss for both the third quarter and the first nine months of 2024.
• Selling, general, and administrative expenses increased significantly, impacting profitability.
• The sale of the Enabling Services Segment resulted in a loss on disposal of $23.2 million.

Risks

• The company is experiencing challenges in its transition to a standalone entity, leading to increased expenses.
• The company's revenue is declining due to lower service revenues and decreased pass-through costs.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is exposed to market risks, including changes in foreign currency exchange rates and interest rates.
• The company's backlog may not be a consistent indicator of future revenue due to various factors, including project cancellations and scope changes.

Future Outlook

The company believes its existing cash, cash flows from operations, and credit facilities will be sufficient to cover its needs for at least the next 12 months. The company will continue to evaluate strategic opportunities, including potential acquisitions and investments.

Management Comments

• Management is focused on remediating material weaknesses in internal controls.
• Management believes the sale of the Enabling Services Segment will allow for greater focus on the core Clinical Services segment.
• Management is actively implementing a comprehensive remediation plan to address material weaknesses in internal controls.

Industry Context

The CRO industry is experiencing growing global demand for clinical development services. Fortrea is positioning itself to meet this demand through its flexible delivery models and global scale. However, the company is facing challenges in its transition to a standalone entity, which is impacting its financial performance.

Comparison to Industry Standards

• The revenue decline of 5.4% in Q3 2024 is worse than some of its peers in the CRO industry, which have shown more stable or positive growth.
• The increase in selling, general, and administrative expenses is higher than industry averages, indicating potential inefficiencies in the company's operations post-spin-off.
• The company's net loss is a concern compared to industry leaders who are generally profitable.
• The company's backlog of $7.6 billion is comparable to other mid-sized CROs, but the conversion of backlog to revenue is a key area to monitor.
• Compared to companies like IQVIA and ICON, Fortrea's financial performance is weaker, reflecting the challenges of its recent spin-off and strategic changes.

Related Party Transactions

• The company had transactions with Labcorp prior to the spin-off, including allocations of corporate expenses and services provided under the Transition Services Agreement.

Stakeholder Impact

• Shareholders are negatively impacted by the net losses and declining revenue.
• Employees may be affected by restructuring and cost-cutting measures.
• Customers may be impacted by the company's strategic changes and transition.
• Creditors may be concerned about the company's financial performance and debt levels.

Next Steps

• The company will continue to implement its remediation plan to address material weaknesses in internal controls.
• The company will focus on its core Clinical Services segment following the sale of the Enabling Services Segment.
• The company will continue to evaluate strategic opportunities, including potential acquisitions and investments.

Key Dates

Keywords

Clinical Research Organization, CRO, Clinical Trials, Pharmaceutical, Biotechnology, Medical Device, Revenue, Net Loss, Backlog, Spin-off, Discontinued Operations, Financial Results, Fortrea